- UroToday Home
- Recent Abstracts
- Urologic Oncology
- Prostate Cancer
Conferences
ANZUP Mini ASM 2021: Cross-Fire Debate: Waiting for Overall Survival Data Is Both Unnecessary and Potentially Harmful
October 18, 2021
ANZUP Mini ASM 2021: Wishful Thinking - Optimal Therapy for Systemic Therapy in Upper Tract Urothelial Carcinoma
October 18, 2021
ANZUP Mini ASM 2021: The Trials and Tribulations of Managing Men With Metastatic Hormone-Sensitive Prostate Cancer
October 18, 2021
ANZUP Mini ASM 2021: Trial Updates: Germ Cell Tumors
October 18, 2021
ANZUP Mini ASM 2021: Trial Updates: Bladder and Penile Cancer
October 18, 2021
ANZUP Mini ASM 2021: Trial Updates: Renal Cell Carcinoma
October 18, 2021
APCCC 2021: DNA Repair Defect Aberrations – What Are the Differences Between Them and What Is the Impact on Patient Management?
October 10, 2021
APCCC 2021: Contagious Enthusiasm in PSMA-Driven Therapeutics
October 9, 2021
APCCC 2021: Who Needs Germline Testing – Prostate Cancer
October 9, 2021
APCCC 2021: Who Needs Germline Testing for Prostate Cancer and What Should Be Tested?
October 9, 2021
APCCC 2021: Tumor Molecular Testing – Tissue vs Liquid Biopsy
October 9, 2021
APCCC 2021: Novel and Not So Novel Agents and Where To Place Them in the Treatment Sequence for Prostate Cancer
October 9, 2021
APCCC 2021: The Role of Somatic Tumor Testing – Implications for Treatment With PARP Inhibitors
October 9, 2021
APCCC 2021: Best Use of Lutetium-PSMA and Where To Put It in Sequencing Therapies Including Treatment Monitoring
October 9, 2021
